INO — Inovio Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $63.81m
- -$30.30m
- $0.22m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.93 | ||
| Price to Tang. Book | 0.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 293.04 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -144.34% | ||
| Return on Equity | -115.42% | ||
| Operating Margin | -51615.96% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.41 | 1.77 | 10.26 | 0.83 | 0.22 | 3.04 | 21.6 | -44.44% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Directors
- Simon Benito NEC (76)
- Jong Kim CEO (52)
- Jay Shepard NVC
- Peter Kies CFO (57)
- Jacqueline Shea COO (55)
- Asli Gevgilili CHO
- Laurent Humeau CSO (54)
- Robert Crotty GCN (47)
- Gene Kim OTH
- Mark Twyman OTH
- Roger Dansey DRC (64)
- David Weiner DRC (65)
- Ann Miller IND (63)
- Wendy Yarno IND (66)
- Lota Zoth IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 15th, 2001
- Public Since
- December 8th, 1998
- No. of Shareholders
- 65
- No. of Employees
- 134
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 36,673,464
- Address
- 660 W. Germantown Pike, Suite 110, PLYMOUTH MEETING, 19462
- Web
- https://www.inovio.com/
- Phone
- +1 8584103134
- Auditors
- Ernst & Young LLP
Upcoming Events for INO
Inovio Pharmaceuticals Inc Annual Shareholders Meeting
Inovio Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Inovio Pharmaceuticals Inc Earnings Release
Similar to INO
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Inovio Pharmaceuticals share price?
As of Today at 21:18 UTC, shares in Inovio Pharmaceuticals are trading at $1.74. This share price information is delayed by 15 minutes.
How has the Inovio Pharmaceuticals share price performed this year?
Shares in Inovio Pharmaceuticals last closed at $1.74 and the price had moved by -84.28% over the past 365 days. In terms of relative price strength the Inovio Pharmaceuticals share price has underperformed the S&P500 Index by -85.22% over the past year.
What are the analyst and broker recommendations for Inovio Pharmaceuticals?
The overall consensus recommendation for Inovio Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Inovio Pharmaceuticals dividend yield?
Inovio Pharmaceuticals does not currently pay a dividend.
Does Inovio Pharmaceuticals pay a dividend?
Inovio Pharmaceuticals does not currently pay a dividend.
When does Inovio Pharmaceuticals next pay dividends?
Inovio Pharmaceuticals does not currently pay a dividend.
How do I buy Inovio Pharmaceuticals shares?
To buy shares in Inovio Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Inovio Pharmaceuticals?
As of the previous close price of $1.74, shares in Inovio Pharmaceuticals had a market capitalisation of $63.81m.
Where are Inovio Pharmaceuticals shares listed?
Here are the trading details for Inovio Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: INO
What kind of share is Inovio Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Inovio Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Inovio Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Inovio Pharmaceuticals is $7.83. That is 350% above the last closing price of $1.74.
Analysts covering Inovio Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.36 for the next financial year.
Find out moreWhat is the trend in the Inovio Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inovio Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -65.63%.
As of the last closing price of $1.74, shares in Inovio Pharmaceuticals were trading -63.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Inovio Pharmaceuticals PE Ratio?
The Inovio Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Inovio Pharmaceuticals?
Inovio Pharmaceuticals' management team is headed by:
- Simon Benito - NEC
- Jong Kim - CEO
- Jay Shepard - NVC
- Peter Kies - CFO
- Jacqueline Shea - COO
- Asli Gevgilili - CHO
- Laurent Humeau - CSO
- Robert Crotty - GCN
- Gene Kim - OTH
- Mark Twyman - OTH
- Roger Dansey - DRC
- David Weiner - DRC
- Ann Miller - IND
- Wendy Yarno - IND
- Lota Zoth - IND